Mail

1093.HK - CSPC Pharmaceutical Group Limited

HKSE - HKSE Delayed Price. Currency in HKD

17.400

-0.040 (-0.23%)

At close: 4:08PM HKT

Stock chart is not supported by your current browser

Previous Close	17.440
Open	17.280
Bid	17.380 x 0
Ask	17.400 x 0
Day's Range	16.700 - 17.460
52 Week Range	14.560 - 26.750
Volume	29,416,133
Avg. Volume	33,950,746

Market Cap	108.547B
Beta (3Y Monthly)	0.81
PE Ratio (TTM)	38.26
EPS (TTM)	0.455
Earnings Date	Aug 20, 2018 - Aug 24, 2018
Forward Dividend & Yield	0.15 (0.81%)
Ex-Dividend Date	2018-05-30
1y Target Est	23.41

All

News

Press Releases

Reuterslast month
BRIEF-Cspc Pharmaceutical Enters License Deal With Sinocelltech For Anti-CD20 Monoclonal Antibody
Oct 8 (Reuters) - CSPC Pharmaceutical Group Ltd: * ENTERS DEAL WITH SINOCELLTECH TO LICENSE AND COMMERCIALIZE ANTI- CD20 MONOCLONAL ANTIBODY FOR INJECTION DEVELOPED BY SINOCELLTECH * CO TO PAY SINOCELLTECH ...
Zacks2 months ago
Verastem Out-Licenses China Rights to Cancer Drug Copiktra
Verastem (VSTM) out-licenses rights to develop/commercialize its newly approved cancer drug Copiktra to the Chinese entity, CSPC Pharmaceutical.
Reuters2 months ago
BRIEF-CSPC Pharmaceutical Announces Exclusive Product License Agreement With Verastem Inc
Sept 26 (Reuters) - CSPC Pharmaceutical Group Ltd: * ENTERED INTO AN EXCLUSIVE PRODUCT LICENSE AND COLLABORATION AGREEMENT WITH VERASTEM, INC * DEAL IN RELATION TO DEVELOPMENT AND COMMERCIALIZATION OF ...
Reuters2 months ago
BRIEF-CSPC Pharmaceutical Group Ltd And Verastem Oncology Sign Exclusive License Agreement
Sept 25 (Reuters) - CSPC Pharmaceutical Group Ltd: * CSPC PHARMACEUTICAL GROUP LIMITED AND VERASTEM ONCOLOGY SIGN EXCLUSIVE LICENSE AGREEMENT FOR THE DEVELOPMENT AND COMMERCIALIZATION OF COPIKTRA™ (DUVELISIB) ...
Business Wire2 months ago
CSPC Pharmaceutical Group Limited and Verastem Oncology Sign Exclusive License Agreement for the Development and Commercialization of COPIKTRA™ (duvelisib) in China
Verastem, Inc. (VSTM) (Verastem Oncology or the Company), focused on developing and commercializing medicines to improve the survival and quality of life of cancer patients, and CSPC Pharmaceutical Group Limited (1093.HK) (CSPC), a leading pharmaceutical company in China, today announced their entry into an exclusive licensing agreement for CSPC to develop and commercialize Verastem Oncology’s COPIKTRA™ (duvelisib), an oral inhibitor of phosphoinositide 3-kinase (PI3K), and the first approved dual inhibitor of PI3K-delta and PI3K-gamma, for the treatment of all oncology indications in China. CSPC will have the right to collaborate with Verastem Oncology on certain global development and clinical trial activities and will share pro-rata in the cost.
Reuters3 months ago
BRIEF-CSPC Pharmaceutical Group Says Wang Jinxu Resigned As Executive Director
Aug 30 (Reuters) - CSPC Pharmaceutical Group Ltd: * WANG JINXU RESIGNED AS AN EXECUTIVE DIRECTOR * WANG JINXU REMAINS AS SENIOR VICE PRESIDENT OF COMPANY Source text for Eikon: Further company coverage:...
Reuters3 months ago
BRIEF-CSPC Pharmaceutical Group Appoints Wang Qingxi As An Executive Director
Aug 20 (Reuters) - CSPC Pharmaceutical Group Ltd: * WANG QINGXI WAS APPOINTED AS AN EXECUTIVE DIRECTOR Source text for Eikon: Further company coverage:
PR Newswire3 months ago
CSPC Pharmaceutical Announces 2018 Interim Results
HONG KONG, Aug. 20, 2018 /PRNewswire/ -- CSPC Pharmaceutical Group Limited (1093.HK) ("CSPC Pharmaceutical" or the "Group"), a leading pharmaceutical company in China, is pleased to announce its interim results for the first half year ended 30 June 2018 (the "Period"). During the Period, with a more favourable business environment created by the gradual deepening of the medical reform and full implementation of the new reimbursement drug lists, the Group endeavored to expand its dedicated sales force of each product and strengthened academic-based promotion, accelerating the market development in major cities and hospitals.
Reuters3 months ago
BRIEF-CSPC Pharmaceutical Group Says Unit To Buy 29.9 Pct Stake In CSPC Yuanda For RMB28 Mln
Aug 6 (Reuters) - CSPC Pharmaceutical Group Ltd: * UNIT TO BUY 29.9% EQUITY INTEREST IN CSPC YUANDA FROM CSPC HOLDINGS AT A CONSIDERATION OF RMB28 MILLION Source text for Eikon: Further company coverage:...
Reuters4 months ago
BRIEF-Xinlong Holding Signs Cooperation Framework Agreement With CSPC Pharmaceutical
July 19 (Reuters) - Xinlong Holding Group Co Ltd : * SAYS IT SIGNS COOPERATION FRAMEWORK AGREEMENT WITH CSPC PHARMACEUTICAL Source text in Chinese: https://bit.ly/2LoRmLd Further company coverage: (Reporting ...
Reuters4 months ago
BRIEF-CSPC Pharmaceutical Says U.S. FDA Approved Investigational New Drug Application For "CSPCHA115"
July 10 (Reuters) - CSPC Pharmaceutical Group Ltd: * U.S. FOOD AND DRUG ADMINISTRATION APPROVED INVESTIGATIONAL NEW DRUG APPLICATION FOR "CSPCHA115" Source text for Eikon: Further company coverage:...
Reuters4 months ago
BRIEF-Cspc Pharmaceutical Group Says Captopril Tablets Granted Approval
July 10 (Reuters) - CSPC Pharmaceutical Group Ltd: * CAPTOPRIL TABLETS GRANTED APPROVAL BY CHINA DRUG ADMINISTRATION * CAPTOPRIL TABLETS GRANTED APPROVAL FOR PASSING CONSISTENCY OF QUALITY AND EFFICACY ...
Reuters4 months ago
BRIEF-CSPC Pharmaceutical Group Appoints Zhang Cuilong As An Executive Director
July 9 (Reuters) - CSPC Pharmaceutical Group Ltd: * ZHANG CUILONG APPOINTED AS AN EXECUTIVE DIRECTOR Source text for Eikon: Further company coverage:
Simply Wall St.5 months ago
Is It Time To Sell CSPC Pharmaceutical Group Limited (HKG:1093) Based Off Its PE Ratio?
This article is intended for those of you who are at the beginning of your investing journey and want to begin learning the link between CSPC Pharmaceutical Group Limited (HKG:1093)’sRead More...
Simply Wall St.5 months ago
Does CSPC Pharmaceutical Group Limited’s (HKG:1093) Recent Track Record Look Strong?
Assessing CSPC Pharmaceutical Group Limited’s (SEHK:1093) performance as a company requires looking at more than just a years’ earnings data. Below, I will run you through a simple sense checkRead More...
Bloomberg6 months ago
China Drugmaker's 65% Rally Just Start for Bullish Analysts
China’s top-performing drugmaker stock may be about to head even higher. At least eight brokers lifted their price targets on CSPC Pharmaceutical Group Ltd. after the company reported a 43 percent surge in first-quarter profit on Friday. The result beat the market’s already high expectations, according to Credit Suisse Group AG, which raised its target by 24 percent -- the most bullish among analysts tracked by Bloomberg.
Reuters6 months ago
BRIEF-CSPC Pharmaceutical Group Appoints Wang Zhenguo as Vice-Chairman And Rotating CEO
May 25 (Reuters) - CSPC Pharmaceutical Group Ltd: * PAN WEIDONG CEASED AS ROTATING CHIEF EXECUTIVE OFFICER * WANG ZHENGUO HAS BEEN APPOINTED AS VICE-CHAIRMAN AND ROTATING CHIEF EXECUTIVE OFFICER * PAN ...
Reuters6 months ago
BRIEF-CSPC Pharmaceutical Group Posts Qtrly Profit Attributable Of HK$909.9 Mln
May 25 (Reuters) - CSPC Pharmaceutical Group Ltd: * QTRLY PROFIT ATTRIBUTABLE HK$909.9 MILLION VERSUS HK$637.9 MILLION * QTRLY TOTAL REVENUE HK$5.39 BILLION VERSUS HK$3.47 BILLION Source text for Eikon: ...
Reuters6 months ago
BRIEF-CSPC Pharmaceutical Group Says Qimaite Drug Granted Approval By China Food And Drug Administration
May 21 (Reuters) - CSPC Pharmaceutical Group Ltd: * GROUP'S "QIMAITE" GRANTED APPROVAL BY CHINA FOOD AND DRUG ADMINISTRATION Source text for Eikon: Further company coverage:
Reuters6 months ago
BRIEF-CSPC Pharmaceutical Group Updates on Drug Registration Approval For Injection By China FDA
May 10 (Reuters) - CSPC Pharmaceutical Group Ltd: * CSPC PHARMACEUTICAL GROUP-"DOXOFYLLINE GLUCOSE FOR INJECTION" GRANTED DRUG REGISTRATION APPROVAL BY CHINA FDA * "DOXOFYLLINE SODIUM CHLORIDE ...
Simply Wall St.7 months ago
Have Investors Priced In CSPC Pharmaceutical Group Limited’s (HKG:1093) Growth?
Let’s talk about the popular CSPC Pharmaceutical Group Limited (SEHK:1093). The company’s shares saw a significant share price rise of over 20% in the past couple of months on theRead More...